The Project

Grifols Egypt for Plasma Derivatives is a joint venture company between the National Service Projects Organization (NSPO) and Grifols. By combining the expertise, technology and resources of both organizations, this strategic partnership seeks to strengthen Egypt’s healthcare system through achieving self-sufficiency of plasma-derived medicines while reinforcing Grifols’ international expansion in the Middle East and Africa.

The scope of the project entails opening 20 plasma donor centers and establishing all required manufacturing facilities to produce essential medicines. This includes testing and warehousing operations, a protein purification plant and a plasma fractionation plant with a capacity of 1 million liters annually that is expected to double in the future.


Grifols Egypt for Plasma Derivatives strives to be the leading producer and supplier of plasma derivatives in the Middle East and Africa and is committed to applying the highest safety and quality standards in compliance with international regulations.


To enhance the quality of Egypt’s healthcare by securing self-sufficiency in safe, high-quality plasma derivatives and to become the main supplier of these products in the Middle East and Africa.


  1. Produce safe plasma derivatives with the highest quality and safety standards.
  2. Securing the availability and self-sufficiency of the plasma derived products in the Arab Republic of Egypt.
  3. Strengthening the healthcare system in Egypt and promoting the health and wellbeing of the Egyptian population.
  4. Establishing industry expertise in Egypt.
  5. To be the Middle East and Africa regional leader in the production and supply of plasma derivatives.
  6. Developing the Egyptian plasma-derivatives market through technology transfer.
  7. Periodic screening of the Egyptian population.


Plasma, essential for human life, is the liquid part of blood. Transparent and with a golden tint, it makes up 55% of blood’s total volume and contains critical proteins responsible for important life functions, such as ensuring that the immune system functions correctly and clotting blood.

blood contains - plasma

For patients lacking these proteins, plasma-derived medicines, are often the only possible treatment for many diseases. They include immunoglobulins for primary and secondary immunodeficiencies and autoimmune disorders, coagulation factors for bleeding disorders, and alpha-1 proteinase inhibitors to treat lung and liver disease. Research is also determining the role of plasma therapies to treat emerging infectious diseases such as COVID-19.

Because plasma is a naturally occurring material – it’s in our body – patients depend on the generosity of healthy volunteer donors for plasma-derived therapies. Long production cycles including rigorous quality and safety checks can take up to a year from donation to manufacture a medicine. Large volumes are needed. As many as 1,200 donations are required to treat just one patient with hemophilia, a bleeding disorder, during a year.

Most plasma is obtained through a process known as plasmapheresis, a technique developed by Grifols in 1951 through which plasma is separated from the other blood components, which are then reinfused into the donor.

Plasmapheresis - Grifols Egypt For Plasma Derivatives

For more information on plasma proteins and their importance, please visit the Plasma Protein Therapeutics Association (PPTA).

About Grifols

Grifols is a global healthcare company that since its founding in Barcelona in 1909 has enhanced the health and well-being of people around the world. Our four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services in more than 100 countries.

As pioneers in the field of plasma science, we are one of the largest plasma companies, with a growing network of donation centers worldwide. We develop this plasma into essential medicines used to treat chronic, rare and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, we also offer a comprehensive portfolio of solutions designed to enhance safety from donation through transfusion. We continue to advance our legacy of innovation by supplying tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care. 

Grifols, with nearly 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry.


For more information, please visit

About NSPO

The National Service Projects Organization (NSPO) was established in Egypt in 1979 to ensure self-sufficiency of the Egyptian Armed Forces demands and to market surplus production both nationally and internationally. The agency is considered one of the leading national institutions supporting the Egyptian economy.

The NSPO is one of the largest companies operating in the production of agricultural fertilizers, industrial gases, solid and liquid alum, chlorine, caustic soda, and different acids, as well as the production of aerosols.

Owning 49 companies in multiple fields, every day the NSPO makes a positive contribution to the Egyptian economy and society.


For more information, please visit

Contact us

Corporate Office

Tolip El Narges Hotel
Teseen Street, Fifth Settlement, Cairo

Contact us

Corp Contact Us Form
Type of consultation *
  • Customer Service
  • Other
I have read and accept the privacy notice.
Data Protection Information
Data controller The Grifols group company to which you have submitted the request
Purpose To respond to your requests for information and/or suggestions
Legal basis Consent
Recipients Grifols group companies
Rights To access, rectify, or erase, as well as any other rights as specified in the additional information layer
Additional information You may access additional and detailed information on data protection here.